The yin and yang of adaptive and maladaptive processes in heart failure

Drug Discovery Today: Therapeutic Strategies

Volumn 9, Issue 4, 2012, Pages

  Bernardo, Bianca C ^a   Ooi, Jenny Y Y ^a   McMullen, Julie R ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE BEHAVIOR; ANGIOGENESIS; ARTICLE; AUTOPHAGY; DISEASE ASSOCIATION; FIBROBLAST; HEART DEVELOPMENT; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HUMAN; INFLAMMATION; INNATE IMMUNITY; MALADJUSTMENT; NONHUMAN; SIGNAL TRANSDUCTION;

EID: 84900795147     PISSN: None     EISSN: 17406773     Source Type: Journal    
DOI: 10.1016/j.ddstr.2013.10.001     Document Type: Review

References (49)

1. B.C. Bernardo et al. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies Pharmacol. Ther. 128 2010 191 227
2. I. Kehat, and J.D. Molkentin Molecular pathways underlying cardiac remodeling during pathophysiological stimulation Circulation 122 2010 2727 2735
3. D. Tirziu et al. Cell communications in the heart Circulation 122 2010 928 937
4. M.L. Martin, and B.C. Blaxall Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends? J. Cardiovasc. Transl. Res. 5 2012 768 782
5. M. Maillet et al. Molecular basis of physiological heart growth: fundamental concepts and new players Nat. Rev. Mol. Cell Biol. 14 2013 38 48
6. K.L. Weeks, and J.R. McMullen The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? Physiology 26 2011 97 105
7. T.A. McKinsey Therapeutic potential for HDAC inhibitors in the heart Annu. Rev. Pharmacol. Toxicol. 52 2012 303 319
8. E. Chung et al. Distinct cardiac transcriptional profiles defining pregnancy and exercise PLoS ONE 7 2012 e42297 10.1371/journal.pone.0042297 http://www.plosone.org
9. J. Li et al. New frontiers in heart hypertrophy during pregnancy Am. J. Cardiovasc. Dis. 2 2012 192 207
10. A.J. Waardenberg et al. Phosphoinositide 3-kinase (PI3K(p110 alpha)) directly regulates key components of the Z-disc and cardiac structure J. Biol. Chem. 286 2011 30837 30846
11. R.H. Ritchie et al. Enhanced phosphoinositide 3-kinase(p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes Diabetologia 55 2012 3369 3381
12. R.C.Y. Lin et al. PI3K(p110α) protects against myocardial infarction-induced heart failure/Identification of PI3K-regulated miRNAs and mRNAs Arterioscler. Thromb. Vasc. Biol. 30 2010 724 732
13. K.L. Weeks et al. Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction Circ. Heart Fail. 5 2012 523 534
14. L. Pretorius et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation Am. J. Pathol. 175 2009 998 1009
15. P. Boström et al. C/EBP beta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling Cell 143 2010 1072 1083
16. M. Volkers et al. Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1 Proc. Natl. Acad. Sci. U. S. A. 110 2013 12661 12666
17. M.M. Montano et al. Inducible re-expression of HEXIM1 causes physiological cardiac hypertrophy in the adult mouse Cardiovasc. Res. 99 2013 74 82
18. K. Lorenz et al. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy Nat. Med. 15 2009 75 83
19. C. Ruppert et al. Interference with ERKThr188 phosphorylation impairs pathological but not physiological cardiac hypertrophy Proc. Natl. Acad. Sci. U. S. A. 110 2013 7440 7445
20. J.W. Gordon et al. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB Circ. Res. 108 2011 1122 1132
21. N. Takeda et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload J. Clin. Invest. 120 2010 254 265
22. R.A. Gottlieb, and R.M. Mentzer Autophagy during cardiac stress: joys and frustrations of autophagy Annu. Rev. Physiol. 72 2010 45 59
23. O.F. Rifki, and J.A. Hill Cardiac autophagy: good with the bad J. Cardiovasc. Pharmacol. 60 2012 248 252
24. Z. Taimeh et al. Vascular endothelial growth factor in heart failure Nat. Rev. Cardiol 10 2013 519 530
25. K-C. Yang et al. Homeostatic regulation of electrical excitability in physiological cardiac hypertrophy J. Physiol. 588 2010 5015 5032
26. K.C. Yang et al. Enhanced cardiac PI3Kalpha signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure Cardiovasc. Res. 93 2012 252 262
27. E.D. Abel, and T. Doenst Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy Cardiovasc. Res. 90 2011 234 242
28. M.G. Rosca et al. Mitochondria in cardiac hypertrophy and heart failure J. Mol. Cell. Cardiol. 55 2013 31 41
29. M. Bayeva et al. Mitochondria as a therapeutic target in heart failure J. Am. Coll. Cardiol. 61 2013 599 610
30. B.T. O'Neill et al. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy Cell Metab. 6 2007 294 306
31. D.L. Mann The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls Circ. Res. 108 2011 1133 1145
32. T. Oka et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure Nature 485 2012 251 255
33. N. Papoutsidakis et al. MicroRNAs and the heart: small things do matter Curr. Top. Med. Chem. 13 2013 216 230
34. M.M. Gladka et al. Small changes can make a big difference - microRNA regulation of cardiac hypertrophy J. Mol. Cell. Cardiol. 52 2012 74 82
35. H.K. Song et al. Deep RNA sequencing reveals novel cardiac transcriptomic signatures for physiological and pathological hypertrophy PLoS ONE 7 2012 e35552
36. S.P. Sheehy et al. Time-warped comparison of gene expression in adaptive and maladaptive cardiac hypertrophy Circ. Cardiovasc. Genet. 2 2009 116 124
37. L.A. Rocha et al. High molecular mass proteomics analyses of left ventricle from rats subjected to differential swimming training BMC Physiol. 12 2012 11
38. B.C. Bernardo et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function Proc. Natl. Acad. Sci. U. S. A. 109 2012 17615 17620
39. C.W. Yancy et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 128 2013 1810 1852
40. K.L. Owen et al. The protective effects of exercise and phosphoinositide 3-kinase (p110alpha) in the failing heart Clin. Sci. (Lond.) 116 2009 365 375
41. R.J. Hajjar Potential of gene therapy as a treatment for heart failure J. Clin. Investig. 123 2013 53 61
42. 2+-ATPase in patients with advanced heart failure Circulation 124 2011 304 313
43. B.C. Bernardo et al. A MicroRNA guide for clinicians and basic scientists: background and experimental techniques Heart Lung Circ. 21 2012 131 142
44. H.L. Janssen et al. Treatment of HCV infection by targeting microRNA N. Engl. J. Med. 368 2013 1685 1694
45. E. van Rooij et al. Developing microRNA therapeutics Circ. Res. 110 2012 496 507
46. R.A. Boon et al. MicroRNA-34a regulates cardiac ageing and function Nature 495 2013 107 110
47. A.H. Chaanine et al. Potential role of BNIP3 in cardiac remodeling, myocardial stiffness, and endoplasmic reticulum: mitochondrial calcium homeostasis in diastolic and systolic heart failure Circ. Heart Fail. 6 2013 572 583
48. P.W.J. Raake et al. Gene therapy targets in heart failure: the path to translation Clin. Pharmacol. Ther. 90 2011 542 553
49. J.R. McMullen, and P.Y. Jay PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart Cell Cycle 6 2007 910 913